## VCYT: Veracyte, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.78 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($42.54)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Guggenheim Raises Price Target for Veracyte (VCYT) to $50.00 | V**
- Source: GuruFocus | 20260105T180945 | Bullish | Relevance: 100%
- Guggenheim has reiterated its 'Buy' rating for Veracyte (VCYT) and increased the price target by 11.11% to $50.00, reflecting continued confidence in the stock. This follows a trend of various analysts raising Veracyte's price targets recently. Veracyte is a genomic diagnostics company specializing in cancer diagnosis and treatment tests for various cancers including prostate, thyroid, breast, and bladder.

**2. Veracyte price target raised to $50 from $45 at Guggenheim**
- Source: TipRanks | 20260105T150945 | Bullish | Relevance: 100%
- Guggenheim analyst Subbu Nambi increased the price target for Veracyte (VCYT) to $50 from $45, while maintaining a Buy rating. This adjustment follows meetings with management teams and updated models for Diagnostic and Life Sciences Tools companies. The firm's updated models incorporate recent information from these companies.

**3. The Truth About Veracyte Inc (VCYT): Silent Biotech Stock That Could Blow Up Your Portfolio**
- Source: AD HOC NEWS | 20260104T090906 | Somewhat-Bullish | Relevance: 100%
- This article evaluates Veracyte Inc (VCYT), a biotech company specializing in cancer diagnostics, as a potential investment. It discusses the company's business model, technology, financial aspects, and risks, comparing it to competitors. The author suggests VCYT is a "long-game position" for investors willing to research and endure volatility, rather than a quick flip or a meme stock.

**4. The Truth About Veracyte Inc (VCYT): Silent Biotech Stock That Could Blow Up Your Portfolio**
- Source: AD HOC NEWS | 20260104T100805 | Neutral | Relevance: 100%
- Veracyte Inc (VCYT) is a biotech company focused on cancer diagnostics that operates quietly while other stocks grab headlines. The article explores whether VCYT, which specializes in genomic diagnostics for early cancer detection, represents a worthwhile long-term investment or is simply another risky biotech stock. It highlights the company's technology, financial performance, and market competition, concluding that it's a "measured cop" for research-heavy portfolios due to its long-term potential despite a lack of current hype.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Guggenheim | $50 | $45 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 21 ($4.55M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 16.5% (+68.9%)
- Vanguard Group Inc: 10.8% (+5.0%)
- Artisan Partners Lim: 9.3% (+16.6%)
- FMR, LLC: 8.6% (-16.2%)
- ARK Investment Manag: 5.7% (+17.5%)

### Key Risks

1. High beta (1.88) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Insider selling cluster: $4.6M in recent transactions.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +8.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.78 indicates undervaluation relative to growth. Balance sheet: strong liquidity (6.2x), low leverage (D/E 0.09). Analyst sentiment positive (1 raises, avg +11%). Insider selling cluster ($4.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.6B |
| Beta | 1.88 |
| 52W Range | $22.61 - $50.71 |
| Short Interest | 7.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.78 |
| Forward P/E | 28.6 |
| Current P/E | 27.8 |
| YoY Growth | -2.9% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -3.2% to 5.2% (+8.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 82nd percentile. MRS_5 at 4.8% confirms short-term momentum alignment. AM_20 at 6.0% shows strong absolute momentum above own 20MA. Outperforming sector by 3.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.22% (CS: 82) | Strong |
| RSI_14 | 62.8 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 1.061x | Above |
| vs SMA50 | 1.081x | Above |
| vs SMA200 | 1.391x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $45.64
- **Stop Loss:** $42.54 (6.8% risk)
- **Target:** $51.84 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 425
- **Position Value:** $19,397.00
- **Portfolio %:** 19.40%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-24 (Est: $0.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.32 | $0.51 | +59.5% |
| 2025Q2 | $0.30 | $0.44 | +48.5% |
| 2025Q1 | $0.20 | $0.31 | +51.3% |
| 2024Q4 | $0.26 | $0.36 | +40.0% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*